Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

[1]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[2]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[3]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[4]  Standards of Medical Care in Diabetes—2017: Summary of Revisions , 2016, Diabetes Care.

[5]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. , 2016, Endocrinology and metabolism clinics of North America.

[6]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[7]  K. Furie,et al.  Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease , 2016, Diabetes Care.

[8]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[9]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[11]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[12]  K. Cusi,et al.  Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease , 2014, Current Hepatology Reports.

[13]  Robert R. Henry,et al.  Prevention of Diabetes With Pioglitazone in ACT NOW , 2013, Diabetes.

[14]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[15]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[16]  Qiwen Ben,et al.  Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies , 2012, International journal of cancer.

[17]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[18]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[19]  D. Houlihan,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[20]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[21]  G. Marchesini,et al.  NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes , 2007, Current diabetes reports.

[22]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[23]  R. DeFronzo,et al.  A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.

[24]  H. Hendrickson.  Prevention of what? , 1983, Journal of the American Optometric Association.